EGFR

Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD
GPCR & G Protein

5-HT Receptor Adenosine Receptor Adenylate Cyclase Adrenergic Receptor Angiotensin Receptor APJ Bombesin Receptor Bradykinin Receptor cAMP Cannabinoid Receptor CaSR CCK receptor CCR CGRP Receptor CRFR CXCR Dopamine Receptor EBI2 Endothelin Receptor Formyl Peptide Receptor Free Fatty Acid Receptor G protein-coupled Bile Acid Receptor GCGR GHSR GLP Receptor Glucagon Receptor GnRH Receptor GPCR19 GPR GPR109A Guanylate Cyclase Hedgehog(Smoothened) ROCK Histamine Receptor ICMT Leukotriene Receptor LPA Receptor LPL Receptor LTR mAChR Melanocortin Receptor Melatonin Receptor mGluR Motilin Receptor MRGPR MT Receptor Neurokinin Receptor Neuropeptide Y Receptor Neurotensin Receptor NPY receptor Opioid Receptor OX Receptor Oxytocin Receptor P2Y Receptor PAFR PAR PKD PKG Prostaglandin Receptor Ras RGS Protein S1P Receptor SGLT Sigma Receptor Somatostatin Receptor TAAR TSH Receptor Urotensin Receptor Vasopressin Receptor

+MORE

EGFR

The receptor tyrosine kinase family of the epidermal growth factor, which also includes HER2/neu (ErbB2), ErbB3 (HER3), and ErbB4 (HER4), includes the epidermal growth factor receptor (EGFR; ErbB1). The extracellular ligand-binding ectodomain, the single chain transmembrane domain, and the intracellular tyrosine kinase domain make up the EGFR, which is located at the cell surface. Epidermal growth factor (EGF), transforming growth factor (TGF-), amphiregulin, heparin-binding EGF, and betacellulin are just a few of the ligands that bind to and activate the EGFR.
The tyrosine kinase domain is activated by the receptors' formation of homo- or heterodimeric complexes after ligand binding. The Ras-Raf-MAP kinase, PI-3K/Akt, PKC, and Stat/Jak signaling pathways are all activated as a result of the dimerization and autophosphorylation of EGFR. The EGFR is activated to control cellular survival, differentiation, and proliferation. The EGFR has been derided as a proto-oncogene primarily because of its function in encouraging cell proliferation and preventing apoptosis.

EGFR related products

Cat No.	Product Name	CAS No.	Product Description
V37821	JBJ-04-125-02 R-isomer	2060610-53-7	JBJ-04-125-02 R-isomer, the R-enantiomer ofJBJ-04-125-02, is a novel, highly potent, mutant-specific, allosteric and orally bioavailable EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M.
V69406	JBJ-09-063	2820336-67-0	JBJ-09-063 is a mutation-selective allosteric EGFR inhibitor (antagonist) with IC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S respectively.
V76864	JBJ-09-063 hydrochloride		JBJ-09-063 HCl is a mutation-selective allosteric EGFR inhibitor (antagonist) with IC50s of 0.147 nM, 0.063 nM, 0.083 nM and EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S respectively.
V76863	JBJ-09-063 TFA		JBJ-09-063 TFA is a mutation-selective allosteric EGFR inhibitor (antagonist) with IC50 of 0.147 nM, 0.063 nM, 0.083 nM and EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S respectively.
V69339	JCN037 (JGK037)	2305154-31-6	JCN037 (JGK037) is a potent, covalent, BBB (blood-brain barrier) permeable (penetrable) EGFR inhibitor (antagonist) with IC50s of 2.49 nM, 3.95 nM and 4.48 nM for EGFR, p-wtEGFR and pEGFRvIII respectively.
V69426	JGK-068S	2490431-16-6	JGK-068S (compound I) is a potent EGFR inhibitor.
V69433	JNJ28871063 hydrochloride	944342-90-9	JNJ28871063 HCl is an orally bioactive, selective and ATP-competitive pan-ErbB kinase inhibitor (antagonist) with IC50s of 22 nM, 38 nM and 21 nM for ErbB1, ErbB2 and ErbB4 respectively.
V69347	Laprituximab (J2898A)	1622327-38-1	Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that may be utilized to prepare the ADC IMGN289.
V69411	Larotinib	1438072-11-7	Larotinib is a potent, broad-spectrum, orally bioactive tyrosine kinase inhibitor (TKI) with EGFR as its primary target, with IC50 of 0.6 nM.
V69405	larotinib mesylate hydrate	2097129-93-4	Larotinib mesylate hydrate is a potent, broad-spectrum, orally bioactive tyrosine kinase inhibitor (TKI) with EGFR as the main target, with IC50 of 0.6 nM.
V23069	Lavendustin A	125697-92-9	Lavendustin A, formerly known as RG 14355, is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 11 nM).
V69352	Losatuxizumab (ABT-806)	1801544-27-3	Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody (mAb).
V69443	Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody)	1448327-63-6	Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody (mAb) for use in cancer-related research.
V79896	MAPK-IN-2		MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor (antagonist) with anti-tumor activity.
V5224	MTX-211	1952236-05-3	MTX-211 is a novel and potent dual inhibitor of EGFR and PI3K with the potential to be used for the treatment of cancer, in particular KRAS mutant colorectal cancer.
V80854	MTX-241F		MTX-241F is a selective small molecule inhibitor targeting EGFR and PI3 kinase family members.
V79895	Multi-target kinase inhibitor 2		Multi-target kinase inhibitor 2 (compound 5K) is a multi-targeted kinase inhibitor (antagonist) with the activity of inhibiting EGFR, Her2, VEGFR2 and CDK2 enzymes.
V69368	N-Desmethyl dosimertinib-d5	2719691-00-4	N-Desmethyl dosimertinib-d5 is the deuterated form of dosimertinib.
V69374	N-Methyl-dosimertinib-d5	2719690-98-7	N-Methyl-dosimertinib-d5 is the deuterated form of dosimertinib.
V26243	Naquotinib mesylate	1448237-05-5	Naquotinib mesylate (ASP-8273; ASP8273), the mesylate salt ofNaquotinib, is anirreversible/covalent and third-generation epidermal growth factor receptor (EGFR) inhibitor with potential anticancer activity.